A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

Background ME-143, a second-generation tumor-specific NADH oxidase inhibitor, is broadly active against human cancers in vitro and in vivo. This first-in-human dose-escalation study evaluated the dose-limiting toxicities (DLTs), pharmacokinetics, safety, tolerability, and preliminary anti-tumor acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Pant, Shubham, Burris, Howard A., Moore, Kathleen, Bendell, Johanna C., Kurkjian, Carla, Jones, Suzanne F., Moreno, Ofir, Kuhn, John G., McMeekin, Scott, Infante, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913846/
https://www.ncbi.nlm.nih.gov/pubmed/23525756
http://dx.doi.org/10.1007/s10637-013-9949-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913846/
https://www.ncbi.nlm.nih.gov/pubmed/23525756
http://dx.doi.org/10.1007/s10637-013-9949-4

Ejemplares similares